2023考研英語閱讀博姿藥房與沃爾格林藥房
Boots and Walgreens
博姿藥房與沃爾格林藥房
A new prescription
新處方
Two huge pharmacy chains become even bigger
兩家大型醫(yī)藥連鎖規(guī)模變得更大了
OTHER American executives may be fretting about Europe.
其他美國總裁們還可能在擔(dān)憂歐洲的狀況，
Not so Greg Wasson, the chief executive of Walgreens, America s biggest pharmacy chain.
但美國最大的醫(yī)藥連鎖沃爾格林藥房總裁Greg Wasson不以為然。
On June 19th his firm said it would buy 45% of Alliance Boots, Europe s largest player in thedrugs-distribution business.
6月19日該公司宣布將購入歐洲最大的藥品經(jīng)銷商英國聯(lián)合博姿藥房45%的股份。
And the $6.7 billion bid is only the first half of a bigger deal.
而這67億美元的出價僅僅是整個收購計劃的上半場罷了。
If all goes as planned, Walgreens will pay about $9.5 billion for the rest of Alliance Bootswithin three yearscreating what the bosses of both firms call the first global pharmacy-ledhealth and well-being enterprise.
如果一切按計劃進(jìn)行，沃爾格林藥房在三年內(nèi)可再付95億美元將剩下的股份一并收購。這將創(chuàng)造兩家公司總裁稱之為 第一家全球性醫(yī)藥和保健企業(yè)
The merged firm will indeed be moreglobal than any pharmacy chain before.
合并后的企業(yè)的確將比任何一家醫(yī)藥連鎖都要全球化。
Walgreens has 8,000 stores in America, with sales of $72 billion in fiscal 2011.
沃爾格林藥房在美國擁有8000家門戶，2011財年銷售額為720億美元。
Alliance Boots is a giant in Europe and beyond.
聯(lián)合博姿藥房是歐洲及其它地區(qū)的巨頭。
The firm, which generated sales of 25 billion in fiscal 2011, operates in more than 25countries and has more than 3,000 pharmacies.
2011財年完成銷售達(dá)250億英鎊，在超過25個國家經(jīng)營業(yè)務(wù)，門店超過3000家。
Together, Walgreens and Alliance Boots will be the world s biggest buyer of prescriptiondrugs.
加在一起，沃爾格林藥房和聯(lián)合博姿藥房將是世界上最大的處方藥采購商。
For Walgreens, the deal follows a fitful year.
對沃爾格林藥房來說，這次收購發(fā)生在不太順利的一年里。
A spat with Express Scripts, which manages drug costs for employers, meant that ExpressScripts customers had to fill their prescriptions elsewhere.
和管理雇主藥品成本的Express Scripts公司分道揚(yáng)鑣，意味著Express Scripts的顧客需要在其他公司購買處方藥。
Sales in the most recent quarter were 3.4% lower than in the same period last year, and thenumber of prescriptions filled dropped by 8.4%.
銷售額在最近的一季度同比下跌3.4%，處方藥銷售數(shù)量下降8.4%。
Although too big to be considered a direct response to these problems, the deal with AllianceBoots gives Walgreens a path to growth after this rough patch.
這次收購的金額顯示這應(yīng)該不是僅僅對這次分家的回應(yīng)，而這次收購也給經(jīng)過這次顛簸的沃爾格林藥房指向了一條發(fā)展的明路。
As for Boots, it is best known for its ubiquity in Britain.
而博姿藥房則在英國以無所不在而聞名。
In 2006 it merged with Alliance UniChem, a European drugs wholesaler and distributor.
2006年博姿藥房并購了歐洲的藥品批發(fā)經(jīng)銷商Alliance UniChem。
One year later Stefano Pessina, the firm s executive chairman, and KKR, a private-equityfirm, took the company private.
一年后公司執(zhí)行主席Stefano Pessina與私募KKR公司一起將公司私有化。
The leveraged buy-out, which was worth 11.1 billion, remains Europe s biggest.
通過價值111億英鎊的杠桿收購后，這單收購至今仍是歐洲最大的。
The deal with Walgreens fulfils Mr Pessina s ambition to bring Boots to America.
這次收購?fù)瓿闪薖essina帶領(lǐng)博姿藥房進(jìn)入美國的雄心壯志。
The country s drugs market is the world s biggest and has formidable establishedpharmacy chains, including, in addition to Walgreens, CVS and Rite Aid.
美國的藥品市場是世界上最大的，同時也存在大得令人可怕的醫(yī)藥連鎖商。
It would be suicide to come in and compete with these guys, Mr Pessina told yourcorrespondent in May. Now he does not have to.
除沃爾格林藥房外，還有CVS和Rite Aid。五月份Pessina跟您的記者描述， 進(jìn)入這個市場跟這些人競爭簡直就是自殺。 現(xiàn)在他或許不再需要了。
The benefits of the merger are many, at least according to Messrs Wasson and Pessina.
并購的好處有很多，至少根據(jù)Messrs Wasson和Pessina的說法。
They say that they will use their combined expertise and strength to streamlinedistribution and squeeze discounts from generic drugmakers.
他們將發(fā)揮聯(lián)合以后的專業(yè)和特長以流程化配送并從通用制藥商榨取更多折扣。
Boots will be able to sell its products, such as the No7 beauty line, at Walgreens Americanstores.
博姿藥房將獲許在沃爾格林藥房的商店銷售自己的產(chǎn)品例如No7系列化妝品。
Walgreens, meanwhile, will benefit from Boots s product-development teams and globalreach.
沃爾格林藥房與此同時也將從博姿藥房的產(chǎn)品開發(fā)團(tuán)隊和全球化。
Even without additional deals, the merged firm hopes to reach revenues of $130 billion by2023, with about one-third coming from operations outside the United States.
哪怕該并購沒有進(jìn)入第二階段，公司合并后營業(yè)額在2023年度將有望達(dá)到1300億美元，其中大約三分之一來自在美國外的業(yè)務(wù)。
Not everybody is convinced.
但并不是所有人都信服。
It is hardly an opportune time to invest in Europe, sceptics say.
持懷疑態(tài)度的稱，現(xiàn)在并不是一個投資歐洲的機(jī)會。
Walgreens s share price dipped by 5.9% on the day of the announcement.
沃爾格林藥房股票在宣布當(dāng)天下跌5.9%。
Standard Poor s, a ratings agency, worries about the debt Walgreens will shoulder.
標(biāo)普對沃爾格林藥房所承擔(dān)的債務(wù)表示擔(dān)憂。
In the first stage of the deal the firm will assume $3.5 billion;
在收購的第一階段，該公司將記帳35億美元債務(wù)。
in the second stage it will take on the rest of Alliance Boots s outstanding debt, whichamounted to more than 7 billion in March.
在第二階段，該公司將承擔(dān)聯(lián)合博姿藥房所有的債務(wù)。截至今年三月份為止，金額達(dá)70億英鎊。
The debate about the merits of the deal is likely to go on for some time.
對這場收購有點的爭論必定將持續(xù)一段時間。
Yet there is already one clear winner.
但現(xiàn)已有一位贏家。
KKR invested 1.2 billion in 2007.
KKR在2007年投資了12億英鎊。
In the first stage of the Walgreens deal, KKR will receive 1.2 billion and 140m in shares.
而在沃爾格林藥房收購的第一階段，KKR將獲得12億英鎊現(xiàn)金和價值1億4千萬英鎊的股份。
If the full acquisition proceeds as expected, the American firm will more than double itsmoneynot bad for an investment framed by a financial collapse and the euro crisis.
如果整個收購方案按計劃進(jìn)行，這家美國公司將使其投資翻番。對于一個在金融坍塌和歐元危機(jī)的大條件下，這份投資還是不錯的。
詞語解釋
1.pharmacy n.藥房;配藥學(xué)，藥學(xué)
He spent four years studying pharmacy.
他花了4年時間學(xué)習(xí)藥劑學(xué)。
2.executive n.總經(jīng)理;行政部門
She s a senior executive in a computer company.
她在一家計算機(jī)公司擔(dān)任高級行政人員。
3.alliance n.結(jié)盟，同盟，聯(lián)盟
An uneasy alliance between the two parties.
兩黨之間不穩(wěn)定的聯(lián)盟。
4.merge v.混合;相融;融入
Other exchanges have to merge to survive.
其他交易所為了生存不得不合并。
5.generate v.形成，造成;產(chǎn)生物理反應(yīng)
Generate reports on management request.
根據(jù)管理需求生成各種報表。
Boots and Walgreens
博姿藥房與沃爾格林藥房
A new prescription
新處方
Two huge pharmacy chains become even bigger
兩家大型醫(yī)藥連鎖規(guī)模變得更大了
OTHER American executives may be fretting about Europe.
其他美國總裁們還可能在擔(dān)憂歐洲的狀況，
Not so Greg Wasson, the chief executive of Walgreens, America s biggest pharmacy chain.
但美國最大的醫(yī)藥連鎖沃爾格林藥房總裁Greg Wasson不以為然。
On June 19th his firm said it would buy 45% of Alliance Boots, Europe s largest player in thedrugs-distribution business.
6月19日該公司宣布將購入歐洲最大的藥品經(jīng)銷商英國聯(lián)合博姿藥房45%的股份。
And the $6.7 billion bid is only the first half of a bigger deal.
而這67億美元的出價僅僅是整個收購計劃的上半場罷了。
If all goes as planned, Walgreens will pay about $9.5 billion for the rest of Alliance Bootswithin three yearscreating what the bosses of both firms call the first global pharmacy-ledhealth and well-being enterprise.
如果一切按計劃進(jìn)行，沃爾格林藥房在三年內(nèi)可再付95億美元將剩下的股份一并收購。這將創(chuàng)造兩家公司總裁稱之為 第一家全球性醫(yī)藥和保健企業(yè)
The merged firm will indeed be moreglobal than any pharmacy chain before.
合并后的企業(yè)的確將比任何一家醫(yī)藥連鎖都要全球化。
Walgreens has 8,000 stores in America, with sales of $72 billion in fiscal 2011.
沃爾格林藥房在美國擁有8000家門戶，2011財年銷售額為720億美元。
Alliance Boots is a giant in Europe and beyond.
聯(lián)合博姿藥房是歐洲及其它地區(qū)的巨頭。
The firm, which generated sales of 25 billion in fiscal 2011, operates in more than 25countries and has more than 3,000 pharmacies.
2011財年完成銷售達(dá)250億英鎊，在超過25個國家經(jīng)營業(yè)務(wù)，門店超過3000家。
Together, Walgreens and Alliance Boots will be the world s biggest buyer of prescriptiondrugs.
加在一起，沃爾格林藥房和聯(lián)合博姿藥房將是世界上最大的處方藥采購商。
For Walgreens, the deal follows a fitful year.
對沃爾格林藥房來說，這次收購發(fā)生在不太順利的一年里。
A spat with Express Scripts, which manages drug costs for employers, meant that ExpressScripts customers had to fill their prescriptions elsewhere.
和管理雇主藥品成本的Express Scripts公司分道揚(yáng)鑣，意味著Express Scripts的顧客需要在其他公司購買處方藥。
Sales in the most recent quarter were 3.4% lower than in the same period last year, and thenumber of prescriptions filled dropped by 8.4%.
銷售額在最近的一季度同比下跌3.4%，處方藥銷售數(shù)量下降8.4%。
Although too big to be considered a direct response to these problems, the deal with AllianceBoots gives Walgreens a path to growth after this rough patch.
這次收購的金額顯示這應(yīng)該不是僅僅對這次分家的回應(yīng)，而這次收購也給經(jīng)過這次顛簸的沃爾格林藥房指向了一條發(fā)展的明路。
As for Boots, it is best known for its ubiquity in Britain.
而博姿藥房則在英國以無所不在而聞名。
In 2006 it merged with Alliance UniChem, a European drugs wholesaler and distributor.
2006年博姿藥房并購了歐洲的藥品批發(fā)經(jīng)銷商Alliance UniChem。
One year later Stefano Pessina, the firm s executive chairman, and KKR, a private-equityfirm, took the company private.
一年后公司執(zhí)行主席Stefano Pessina與私募KKR公司一起將公司私有化。
The leveraged buy-out, which was worth 11.1 billion, remains Europe s biggest.
通過價值111億英鎊的杠桿收購后，這單收購至今仍是歐洲最大的。
The deal with Walgreens fulfils Mr Pessina s ambition to bring Boots to America.
這次收購?fù)瓿闪薖essina帶領(lǐng)博姿藥房進(jìn)入美國的雄心壯志。
The country s drugs market is the world s biggest and has formidable establishedpharmacy chains, including, in addition to Walgreens, CVS and Rite Aid.
美國的藥品市場是世界上最大的，同時也存在大得令人可怕的醫(yī)藥連鎖商。
It would be suicide to come in and compete with these guys, Mr Pessina told yourcorrespondent in May. Now he does not have to.
除沃爾格林藥房外，還有CVS和Rite Aid。五月份Pessina跟您的記者描述， 進(jìn)入這個市場跟這些人競爭簡直就是自殺。 現(xiàn)在他或許不再需要了。
The benefits of the merger are many, at least according to Messrs Wasson and Pessina.
并購的好處有很多，至少根據(jù)Messrs Wasson和Pessina的說法。
They say that they will use their combined expertise and strength to streamlinedistribution and squeeze discounts from generic drugmakers.
他們將發(fā)揮聯(lián)合以后的專業(yè)和特長以流程化配送并從通用制藥商榨取更多折扣。
Boots will be able to sell its products, such as the No7 beauty line, at Walgreens Americanstores.
博姿藥房將獲許在沃爾格林藥房的商店銷售自己的產(chǎn)品例如No7系列化妝品。
Walgreens, meanwhile, will benefit from Boots s product-development teams and globalreach.
沃爾格林藥房與此同時也將從博姿藥房的產(chǎn)品開發(fā)團(tuán)隊和全球化。
Even without additional deals, the merged firm hopes to reach revenues of $130 billion by2023, with about one-third coming from operations outside the United States.
哪怕該并購沒有進(jìn)入第二階段，公司合并后營業(yè)額在2023年度將有望達(dá)到1300億美元，其中大約三分之一來自在美國外的業(yè)務(wù)。
Not everybody is convinced.
但并不是所有人都信服。
It is hardly an opportune time to invest in Europe, sceptics say.
持懷疑態(tài)度的稱，現(xiàn)在并不是一個投資歐洲的機(jī)會。
Walgreens s share price dipped by 5.9% on the day of the announcement.
沃爾格林藥房股票在宣布當(dāng)天下跌5.9%。
Standard Poor s, a ratings agency, worries about the debt Walgreens will shoulder.
標(biāo)普對沃爾格林藥房所承擔(dān)的債務(wù)表示擔(dān)憂。
In the first stage of the deal the firm will assume $3.5 billion;
在收購的第一階段，該公司將記帳35億美元債務(wù)。
in the second stage it will take on the rest of Alliance Boots s outstanding debt, whichamounted to more than 7 billion in March.
在第二階段，該公司將承擔(dān)聯(lián)合博姿藥房所有的債務(wù)。截至今年三月份為止，金額達(dá)70億英鎊。
The debate about the merits of the deal is likely to go on for some time.
對這場收購有點的爭論必定將持續(xù)一段時間。
Yet there is already one clear winner.
但現(xiàn)已有一位贏家。
KKR invested 1.2 billion in 2007.
KKR在2007年投資了12億英鎊。
In the first stage of the Walgreens deal, KKR will receive 1.2 billion and 140m in shares.
而在沃爾格林藥房收購的第一階段，KKR將獲得12億英鎊現(xiàn)金和價值1億4千萬英鎊的股份。
If the full acquisition proceeds as expected, the American firm will more than double itsmoneynot bad for an investment framed by a financial collapse and the euro crisis.
如果整個收購方案按計劃進(jìn)行，這家美國公司將使其投資翻番。對于一個在金融坍塌和歐元危機(jī)的大條件下，這份投資還是不錯的。
詞語解釋
1.pharmacy n.藥房;配藥學(xué)，藥學(xué)
He spent four years studying pharmacy.
他花了4年時間學(xué)習(xí)藥劑學(xué)。
2.executive n.總經(jīng)理;行政部門
She s a senior executive in a computer company.
她在一家計算機(jī)公司擔(dān)任高級行政人員。
3.alliance n.結(jié)盟，同盟，聯(lián)盟
An uneasy alliance between the two parties.
兩黨之間不穩(wěn)定的聯(lián)盟。
4.merge v.混合;相融;融入
Other exchanges have to merge to survive.
其他交易所為了生存不得不合并。
5.generate v.形成，造成;產(chǎn)生物理反應(yīng)
Generate reports on management request.
根據(jù)管理需求生成各種報表。
